Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-11 4:12 pm Sale |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ORBIMED ADVISORS LLC | 158,245 7.900% |
-42,376 (-21.12%) |
Filing History |
| 2022-02-10 5:03 pm Purchase |
2022-02-09 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 201,779 9.900% |
5,732 (+2.92%) |
Filing History |
| 2022-02-10 4:13 pm Purchase |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ELI LILLY & Co LLY |
61,061 3.100% |
61,061 (New Position) |
Filing History |
| 2022-02-10 11:14 am Purchase |
2022-02-09 | 13G | Spyre Therapeutics, Inc. SYRE |
PICTET ASSET MANAGEMENT SA | 98,725 5.000% |
98,725 (New Position) |
Filing History |
| 2022-02-10 09:01 am Sale |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ADAGE CAPITAL PARTNERS GP L.L.C. | 40,000 2.030% |
-79,680 (-66.58%) |
Filing History |
| 2022-02-03 4:41 pm Sale |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BlackRock Inc. BLK |
119,939 6.100% |
-9,660 (-7.45%) |
Filing History |
| 2021-12-16 4:32 pm Purchase |
2021-12-06 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
SUVRETTA CAPITAL MANAGEMENT, LLC | 102,840 5.200% |
102,840 (New Position) |
Filing History |
| 2021-03-19 4:07 pm Purchase |
2021-03-16 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 196,048 9.900% |
346 (+0.18%) |
Filing History |
| 2021-03-05 5:17 pm Unchanged |
2021-02-23 | 13D | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 195,701 9.900% |
0 (Unchanged) |
Filing History |
| 2021-02-16 4:53 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Baker Bros. Advisors LP | 195,701 9.900% |
127,157 (+185.51%) |
Filing History |
| 2021-02-16 3:14 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Point72 Asset Management, L.P. | 117,191 6.100% |
1,672 (+1.45%) |
Filing History |
| 2021-02-16 10:21 am Sale |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Nantahala Capital Management, LLC | 96,560 4.900% |
-17,530 (-15.37%) |
Filing History |
| 2021-02-12 4:59 pm Sale |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Lilly Ventures Fund I LLC | 102,742 5.400% |
-3,227 (-3.04%) |
Filing History |
| 2021-02-12 4:39 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ORBIMED ADVISORS LLC | 200,621 10.250% |
86,000 (+75.03%) |
Filing History |
| 2021-02-11 07:31 am Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
ADAGE CAPITAL PARTNERS GP L.L.C. | 119,680 6.240% |
60,936 (+103.73%) |
Filing History |
| 2021-02-10 11:37 am Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
PICTET ASSET MANAGEMENT SA | 100,773 5.250% |
100,773 (New Position) |
Filing History |
| 2021-02-10 06:35 am Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
LV Management Group LLC | 4,141 0.200% |
4,141 (New Position) |
Filing History |
| 2021-02-02 2:56 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BlackRock Inc. BLK |
129,599 6.800% |
53,107 (+69.43%) |
Filing History |
| 2020-10-26 4:36 pm Purchase |
2020-10-23 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Point72 Asset Management, L.P. | 115,519 6.200% |
115,519 (New Position) |
Filing History |
| 2020-06-09 11:45 am Purchase |
2020-04-30 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
BCLS II Equity Opportunities LP | 108,000 6.100% |
108,000 (New Position) |
Filing History |